PSMA-based Theranostics in Advanced Non-small Cell Lung Cancer: A Hit or a Miss?
Prostate-specific membrane antigen (PSMA) overexpression on prostate cancer cells finally led to the FDA approval of the therapeutic use of 177 Lu-PSMA-617 in metastatic castrate-resistant prostate ca
APA
Aggarwal P, Anwariya A, et al. (2026). PSMA-based Theranostics in Advanced Non-small Cell Lung Cancer: A Hit or a Miss?. Clinical nuclear medicine, 51(2), e120-e122. https://doi.org/10.1097/RLU.0000000000005816
MLA
Aggarwal P, et al.. "PSMA-based Theranostics in Advanced Non-small Cell Lung Cancer: A Hit or a Miss?." Clinical nuclear medicine, vol. 51, no. 2, 2026, pp. e120-e122.
PMID
40065397
Abstract
Prostate-specific membrane antigen (PSMA) overexpression on prostate cancer cells finally led to the FDA approval of the therapeutic use of 177 Lu-PSMA-617 in metastatic castrate-resistant prostate cancer. However, PSMA is also expressed in the neovasculature of other solid tumors, such as lung and renal cancer, making the theranostic potential of 177 Lu-PSMA-617 worth exploring in this setting. Here is such a case of an 83-year-old man with advanced non-small cell lung cancer where the theranostic potential of 177 Lu-PSMA-617 was explored using dosimetric analysis.
MeSH Terms
Humans; Male; Carcinoma, Non-Small-Cell Lung; Lung Neoplasms; Aged, 80 and over; Glutamate Carboxypeptidase II; Antigens, Surface; Heterocyclic Compounds, 1-Ring; Dipeptides; Lutetium; Theranostic Nanomedicine
같은 제1저자의 인용 많은 논문 (3)
- Response Evaluation Criteria in Grade 1/2 Neuroendocrine Tumors (RECIN).
- Metastatic Mimicker in Thyroid Cancer with Thyroglobulin Elevation and an FDG-Avid Recurrent Aneurysmal Bone Cyst.
- Utility of Cross-sectional and Correlative Imaging in Differentiated Thyroid Carcinoma with Unusual Presentation of Adrenal Metastases - Case Series and Review of Literature.